Gonorrhoea cases on the rise across Europe
Following a decline in notification rates in 2016, the number of gonorrhoea cases has gone up by 17% across the reporting EU/EEA countries with more than 89 000 confirmed diagnoses in 2017 – more than 240 cases a day.
Extensively drug-resistant gonorrhoea: risk of further dissemination within and across Europe
ECDC comment on the study 'Detection in the United Kingdom of the Neisseria gonorrhoeae FC428 clone, with ceftriaxone resistance and intermediate resistance to azithromycin, October to December 2018' by Eyre et al. in the Eurosurveillance edition of 7 March 2019.
Gonorrhoea: drug resistance compromises recommended treatment in Europe
Gonorrhoea is the second most commonly notified sexually transmitted infection across the EU/EEA countries with almost 500 000 reported cases between 2007 and 2016. The infection is treatable but Neisseria gonorrhoeae keep showing high levels of azithromycin resistance according to latest results of the European Gonococcal Antimicrobial Surveillance Programme.
Health risks during the Carnival season in Brazil
The Carnival season will last from 1 to 9 March 2019. In Rio de Janeiro, Brazil, 1 million participants are expected, including many travellers from Europe
Call for scientific collaboration to support genomic-based surveillance of Neisseria gonorrhoeae-antimicrobial resistance at EU-level
ECDC is looking to establish a scientific collaboration with an organisation which can perform whole genome sequencing (WGS) of Neisseria gonorrhoeae, carry out related data analyses, share results of the analyses with ECDC and the participants of the European Gonococcal Antimicrobial Surveillance Programme as well as visualise the results.
Drug-resistance of gonorrhoea in the EU: persistent but stable
Neisseria gonorrhoea continues to show high levels of resistance to azithromycin across the European Union and European Economic Area, according to the 2016 results of the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP).
Understanding drug-resistant gonorrhoea: an ECDC whole genome sequencing study
Can whole genome sequencing illustrate changes in drug susceptibility of gonorrhoea to antimicrobials used for treatment and so help to define more effective treatment regimens? The first study of this kind within an international surveillance programme for sexually transmitted infections shows distribution of drug-resistant gonorrhoea strains across Europe.
ECDC: first detected cases of extensively drug-resistant gonorrhoea threaten future treatment
Within a matter of weeks, three cases of gonorrhoea that are resistant to the recommended first line antibiotic treatment have been detected in Europe and Australia. These are the first global reports of Neisseria gonorrhoeae with high-level resistance to azithromycin and ceftriaxone resistance that also show resistance to several other vital antibiotics. At a time with limited alternatives to the current dual therapy, lack of a vaccine and insufficient surveillance capacity in some regions, these cases highlight the growing threat of drug-resistance – which could lead to untreatable gonorrhoea.
Gonorrhoea strains across Europe becoming more susceptible to main treatment options
According to test results from the annual European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP), resistance levels to the main antimicrobials used for treatment of gonorrhoea infection have seen an encouraging decrease since 2010.
Five infectious diseases accounted for 75% of reported cases in EU - summary report
Chlamydia infection, campylobacteriosis, salmonellosis, gonorrhoea and tuberculosis were the most commonly reported notifiable infectious diseases in the EU and EEA in 2014.